Introduction
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutation in the gene encoding methyl-CpGbinding protein 2 (MECP2). Since the first clinical delineation, extensive progress has been achieved in the clinical understanding of RTT, which has been further increased by the finding of the causative gene. In RTT particular signs and symptoms appear age dependently and are thought to be due to abnormal synaptogenesis at different developmental stages caused by mutation of MECP2. Exploration of the role of MeCP2 in RTT is extending not only to the understanding of other developmental disorders but also normal brain development.
In this review, papers published mainly in 2004 on the recent clinical and molecular biological advances in RTT are presented. The future direction of research and possible management approaches are discussed.
Clinical signs and symptoms
The neuronal background of the signs and symptoms of RTT have not been completely clarified, but we have shown the pathophysiology to be the early disturbance of monoaminergic systems [1] . The pathognomonic stereotyped hand movement that develops after loss of purposeful hand use and appearance of dystonic hypertonus are thought to be induced by the dysfunction of the basal ganglia, the premoter cortex and the supplementary motor area with dopaminergic receptor supersensitivity [1] . Environmental manipulation was shown to have a relatively limited effect on the frequency of the repetitive hand movement, suggesting that the movement is manifested by automatic reinforcement or neurochemical processes [2 ] .
The abnormal respiratory pattern, another characteristic feature, was investigated by Julu [3] , and an abnormal cardiorespiratory center in the brainstem and involvement of the serotonergic (5HT) system were demonstrated. From the experimental observation in mice that substance P produced slow depolarization in an inspiratory pacemaker and non-pacemaker neurons, the abnormal respiration seen in RTT is suggested to be due to decreased substance P and other neuromodulators in the brainstem [4 ] .
The cause of sudden death in RTT is not fully understood, but alteration of ventricular repolarization is postulated. Significantly lower levels of plasma nerve growth factor in RTT patients with corrected QT interval prolongation may indicate the presence of an altered ventricular repolarization with high risk of cardiac arrhythmias [5 ] . Severe bradycardia required a pacemaker implant in one case suggesting sinus node dysfunction as a possible cause of sudden death [6 ] .
Genotype-phenotype correlation
Genotype-phenotype correlations have been of interest in understanding the broad clinical and severity spectrum of RTT [7 ] . It was pointed out that conflicting results observed in studies on phenotype-genotype correlations in part related to the use of different clinical severity scales, diagnostic criteria and means of stratification by age and mutation group, as well as the possible effects of unbalanced X-chromosome inactivation (XCI) [8 ] . Thus, a revised ordinal scoring system was applied to analyze the phenotypes of 85 patients with the MECP2 mutation, and this revealed that patients with missense mutations had lower total severity scores and better language performance than those with nonsense mutations. No difference was noted between severity scores for mutations in the methyl-binding domain (MBD) and transcriptional repression domain (TRD). However, patients with missense mutations in TRD had the best overall scores and better preservation of head growth and language skills [8 ] .
Using the Australian RTT data base [9 ] , it was found that mutations in the nuclear localization signal (NLS) region within the TRD location were significantly more severe. However, the only difference between TRD and MBD was observed in voluntary hand use, where the MBD group retained more use. A less severe phenotype was found in the region after the TRD-NLS including the C-terminal region. R270S, located in the NLS of the TRD, was the most severe of the common mutations, while R294X, found in the TRD but after the NLS had a milder phenotype. Analysis of the entire coding region of MECP2 in 42 sporadic RTT patients revealed that patients with a nonsense mutation in TRD tend to show earlier onset of progression and more severe language retardation than patients with mutations in the MBD [10 ] .
Characteristics of phenotypes caused by mutations in the C-terminal of MECP2 were reported. In patients with hot-spot deletions in the C-terminus, dystonia is present from childhood and results in a serious spine deformity; however, their adaptive behavior is surprisingly preserved [11 ] . A 19-year-old woman with a novel C-terminal MECP2 frameshift deletion (1135-1142del CCCGTG CC) had mental retardation and epilepsy, but language, purposeful hand use and locomotion were preserved and stagnation of head growth was not observed [12 ] .
The group II WW domain binding region is localized from residue 325 to the C-terminus with the interacting proline-rich sequence at its center. Effects of X-chromosome inactivation on phenotype
All of the studies analyzing the coding region observed modulation of phenotype by the pattern of XCI [8 ,9
,10 ]. The impact of specific mutations coupled with possible variation in XCI must be considered carefully in the derivation of phenotype-genotype correlation [8 ] . However, there is no evidence of skewed XCI in the R133C group which showed less severe scores in the overall clinical severity score [7 ] .
Effects of X-chromosome inactivation on phenotype in animal experiments
To evaluate the influence of XCI on the phenotypic outcome of MECP2 mutation, the pattern of XCI at the single cell level in the brains of heterozygous female RTT mouse models was studied [14 ] . XCI patterns were unbalanced, favoring expression of the wild-type allele, in most mutant females and none of the animals had nonrandom XCI favoring mutant alleles. Primary neuronal cultures from MeCP2-mutant mice showed selective survival of neurons in which the wild-type X chromosome was active.
In the targeted MeCP2 mouse model, Mecp 2 (À/þ) female mice exhibited uniform regional distribution of the Mecp2 mutation-expressing cells in the brain, but unbalanced XCI in the population, favoring expression of the Mecp2 wild-type allele. Mecp2 expression in Mecp2-expressing cells from Mecp2 (À/þ) mice was significantly lower than those from Mecp2 (þ/þ) agematched controls. The negative effect of the Mecp2 mutation on wild-type Mecp2 expression correlated with the percentage of Mecp2 mutation-expressing cells in the cortex [15 ] . Similar results were obtained in two RTT females with identical MECP2 mutations but different XCI ratios [15 ] .
MeCP2 proteins may play a significant role in histone modification. Whether MeCP2 is necessary for an inactive X histone modification pattern was investigated by studying cells of ICF (Immune deficiency, Centromeric region instability, and Facial anomalies) syndrome and RTT, and it was shown that the inactive X in both disorders exhibited a normal histone modification pattern [16 ] . These results suggest that DNA methylation and the associated methyl-DNA binding proteins may not play a critical role in determining histone modification patterns on the mammalian inactive X chromosome at the sites analyzed.
Mechanisms for differences in genotype affecting phenotype
A Xenopus laevis protein of 20 kDa, p20, is a novel protein which is able to interact in vivo and in vitro with MeCP2. This protein also can stabilize human endogenous MeCP2 and the MeCP2 residue localized between the MBD and TRD is its primary interaction surface. This may relate to a decrease in MeCP2 stability observed in some RTT mutations [17 ] . By using mouse L929 cells and Drosophila SL2 cells missense mutations in MBD were shown to cause specific abnormalities in the function of the MeCP2 protein [18] . Expression analysis of neuron-related cell lines revealed overexpression of numerous genes in RTT patients compared with control samples [19 ] , including palmitylated membrane protein I (MPPI), zinc finger domain protein (FHLI), and phosphoglycerate kinase I (PGKI) located on the X chromosome and neuroepithelial cell transforming gene I (NET I), which as well as MPPI are important for neuronal homeostasis. These genes are also methylated and bound by MeCP2 in neuron-related cells which suggests a role in the pathophysiology of RTT. As the authors mentioned these results provide new data on the underlying mechanism of RTT and unveil a novel target for MeCP2-mediated gene repression. Furthermore, this research could help elucidate the genotype-phenotype correlation of RTT and the relationship of RTT to other developmental neuropsychological disorders.
In the brains of Mecp2-null mice, an imprinted gene cluster on chromosome 6 was found, including Dlx5 and Dlx6 whose transcription was roughly two times greater than that of wild-type mice [20 ] . Because Dlx5 regulates production of enzymes that synthesize GABA, loss of imprinting of Dlx5 may alter GABAergic neuron activity in individuals with RTT.
At the Dlx5-Dlx6 locus, Mecp2 mediates the silent chromatin-derived 11-kb chromatin loop. The loop was absent in chromatin of the brains of Mecp2-null mice, and Dlx5-Dlx6 interacted with far distant active chromatinassociated loops. As the authors suggested, these results show that formation of a silent chromatin loop is a new mechanism underlying gene regulation by Mecp2 [20 ] .
It is not clear whether apoptosis is involved in the disorder under study. The apoptotic process in RTT was examined. It was found that the cells of RTT patients showed a lower percentage of apoptosis under routine conditions than did controls, whereas, in the presence of dRib, the percentage of apoptotic cells in RTT patients increased with time and reached the same percentage as controls at 72 h [21 ] . These data suggest that RTT may be associated with a low susceptibility or an increased resistance to apoptosis.
From the extensive studies of his group, Johnston [22 ] suggests that mutations in MECP2 disrupt formation, maturation and activity-dependent refinement of synapses by failing to suppress expression of genes that need to be turned off during this process.
New isoform of methyl-CpG-binding protein 2 The novel MeCP2 splice variant which includes exon 1 encodes a distinct N-terminus. The new isoform appears to be the evolutionally conserved form. The mRNA of the exon 1 variant had 10-fold greater expression than that of the exon 2 in mouse and human brain [24 ] . Thus the new splice variant MeCP2B (MeCP2 alfa) appears to be the major transcript and most abundant protein isoform [25 ] .
Mnatzakanian et al.
[23 ] found two distinct deletions in exon 1 in 19 girls with typical RTT without mutation of exons 3 and 4, while Evans et al. [26 ] failed to detect an exon 1 mutation in 97 mutation-negative RTT cases. It is necessary and of interest to further assess the similarities and differences in form and function of this novel protein isoform.
Pathogenesis of Rett syndrome and other neurodevelopmental disorders
During certain phases of the disease, girls with RTT display autistic features. In both RTT and autism, delay in development of the sleep-wake cycle and locomotion are the initial signs. Although the affected loci of the brain differ between the two disorders, RTT and autism share certain similarities microscopically [27, 28] ; that is, a decrease in the size of neurons and increased neuronal packing, and a reduction in arborization of dendrites. These data indicate that one of the primary alterations in the brains of girls with RTT and children with autism is a decrease in the number of dendrites and synapses in selective areas of the brain due to impairment of synaptogenesis or as a result of excessive pruning [7 ] .
Glaze [29 ] in his review article suggests that abnormalities in synaptic development and modulation play an important role in the pathophysiology of RTT, and considered that similar processes exist in autism. A significant decrease in MeCP2 expression in tissue samples containing frontal cortex was observed not only in RTT but in several related neurodevelopmental disorders, including autism and Prader-Willi syndrome [30 ], but one sample of a pervasive developmental disorder and one of autism showed an increase in expression.
Transgenic mice with MeCP2 protein expression at approximately two-fold wild-type levels displayed enhanced motor and contextual learning and enhanced synaptic plasticity in the hippocampus at around 10 weeks of age [31 ] . However, after 20 weeks of age, these mice developed seizures and became hypoactive, and approximately 30% of them died by 1 year. These results indicate that several neurodevelopmental disorders show significant differences in MeCP2 expression from agematched controls, and decreased or increased expression of MeCP2 may be involved in abnormal developmental phenotype, and gain of function in MECP2 mutations might underlie some cases of X-linked delayed-onset neurobehavioral disorders.
At least 10 genes are implicated in causing autism, among them changes at 15q11-q13 are one of the fairly frequently detected abnormalities which indicate abnormalities in synaptogenesis [32 ] . Three RTT patients have in fact been shown to be carriers of both a MECP2 mutation and a 15q11-q13 rearrangement [33 ] .
Significant defects in expression of UBE3A/E6AP, a candidate gene for Angelman syndrome, are demonstrated in two different Mecp2-deficient mouse strains and human RTT, Angelman syndrome and autism brains compared to controls [34 ] . Although there was no difference in the allelic expression of several imprinted transcripts in the Mecp2-null brain, UBE3A sense expression was significantly reduced, consistent with the decrease in protein. A nonimprinted gene from 15q11-q13, GABAB3, encoding the beta3 subunit of the GABA receptor, a candidate gene for autism, also showed significantly reduced expression in multiple RTT, Angelman syndrome and autism brains, and Mecp 2-deficient mice by quantitative immunoblot [34 ] .
A higher frequency of missense variants of highly conserved segments of the 3 0 -untranslated region (3 0 -UTR) of MECP2 was observed in autism, and a possible association between MECP2 mutations and autism was suggested [35 ] . It is interesting that these neurodevelopmental disorders commonly show abnormalities in locomotion, and RTT and autism also show abnormal development of the sleep-wake cycle, suggesting abnormalities of the brainstem aminergic neuron and of synaptogenesis. These results suggest a relationship between autism-related genes and the MECP2 gene, and overlapping pathways of gene dysregulation within 15q11-q13 in RTT, Angelman syndrome and autism, and implicate MeCP2 in the regulation of UBE3A and GABRB3 expression in the postnatal mammalian brain. However, analysis of 3 0 -UTR of MECP2 in psychiatric disorders other than autism, that is schizophrenia and 118 cases of nonspecific mental retardation, identified two nonspecific coding sequence variants [35 ] ; neither of these is likely to be causal [36 ] .
MECP2 mutations do not represent a major cause of nonspecific neurodevelopmental disorders. However, in rare cases MECP2 mutations can cause a phenotype reminiscent of Angelman syndrome, but they fail to account for the excess of sporadic patients with a definitive clinical diagnosis of Angelman syndrome [37 ,38 ] .
A girl with Down syndrome who has a R168X mutation in the MECP2 gene in addition to trisomy 21 was reported [39 ] . This patient developed symptoms of RTT at the age of 18 months. Down syndrome has a similar pathophysiology to RTT with postural hypotonia, failure in locomotion and delay in developmental reduction of daytime sleep from late infancy. The appearance of typical stereotyped movements at similar ages to classic RTT suggests that neurons and neuronal systems involved in this sign are specific for RTT and attain certain levels of development in early infancy, and that MeCP2 is not affected by the chromosomal aberration of 21 trisomy.
An X-linked gene and mental retardation
A de-novo missense mutation in the X-linked cyclindependent kinase-like 5 (CDKL5/STK9) gene located within Xp22 was observed in two female patients who had early-onset infantile spasms and severe mental retardation that overlap those of other neurodevelopmental disorders such as RTT and Angelman syndrome [40 ] . A deletion of nucleotide 183 of the coding sequence (c.183delT) in the CDKL5 gene was also observed in a family with identical twin sisters with an autistic disorder and mild-to-moderate intellectual disabilities, and a brother with profound intellectual disability and infantile spasm [41 ] ; their phenotype showed considerable overlap with that of RTT. These results suggest that impaired CDKL5 catalytic activity plays an important role in the pathogenesis of certain neurodevelopmental disorders.
MeCP2 expression during development
Previous studies showed that the timing of appearance of the MeCP2 protein correlates with ontogeny of the central nervous system, and the amount of protein increases with maturation. In humans, an increase in the number of MeCP2-positive cortical neurons is observed during childhood, while deeper structures (such as the reticular formation) show a constant percentage of MeCP2-positive neurons from 35 weeks of gestation [7 ] . Polysomnographical examination of RTT patients revealed abnormalities of a parameter of sleep which has the critical age of development is from 38 weeks of gestation to 4 months after birth [42] . This parameter is considered to be modulated by the aminergic neuron, the noradrenergic neuron of the brainstem [43] , which may mature before 38 weeks of gestation.
The relation of MeCP2 abundance to synapse formation is important to help elucidate the role of MeCP2 in neuronal maturation [7 ] . MeCP2 is found in the nonsynapsed neurons. The presence of MeCP2 does not require synapse formation but the protein level increases when synapses form. The mature neurons that have formed synapses induce full MeCP2 levels.
MeCP2 is required for the formation or maintenance of mature neurons and dendrites in the olfactory epithelium. Olfactory biopsies from girls with RTT were analyzed and an excess of immature neurons was found compared to normal controls, although the overall number of neurons is not significantly different [44] . The mature neurons in RTT are abnormally structured with absent or unusual dendrites, dispersed axons and dysmorphic, small cell bodies.
In a RTT mouse model Mecp2 deficiency leads to a transient delay in the terminal differentiation of olfactory neurons, and disrupts axonal targeting in the olfactory field resulting in abnormal axonal projections, subglomerular disorganization and a persistent reduction in glomerular size [45 ] . This indicates a critical cell biological function for MeCP2 in mediating the final stages of neuronal development [46 ] .
In various brain areas of normal rats the highest expression of Mecp2 protein was observed in the olfactory bulb and frontal cortex, little expression in the caudateputamen system and hippocampus, and except in the olfactory nuclei, very few cells showed detectable Mecp2 protein at birth. The number increased during the first week of age, especially in the cortex and nucleus accumbens [47 ] . This suggests the importance of olfactory biopsies for evaluation of synaptogenesis in human patients.
In rat brain, at early postnatal stages, regions having neurons that were generated early and thus more mature had the strongest Mecp2 expression. Late developing structures including the cortex, hippocampus and cerebellum exhibited the most significant changes in Mecp2 expression, and it is correlated with synaptogenesis in these regions [48 ] . The changes in the cerebellum, particularly of the granule cells, are well correlated with those observed in RTT brain by Johnston et al. [49] .
Neocortical projection layers in Mecp2 -/y mice are thinner than those in wild-type mice, and pyramidal neurons in layer II/III in Mecp2 -/y mice are smaller and less complex than those in wild-type mice [50 ] . These results suggest that MeCP2 is involved in the maturation and maintenance of neurons, including dentritic metaborization, rather than cell decisions.
Selective mutation of Mecp2 in postnatal neurons leads to a similar, although delayed, RTT phenotype in mice, suggesting that MeCP2 plays a role in postmitotic neurons; that is, the symptoms of RTT are exclusively caused by a neuronal MeCP2 deficiency. Luikenhuis et al. [51 ] tried to demonstrate this hypothesis by placing MeCP2 expression under the control of a neuron-specific promoter, and showed that expression of the Mecp2 transgene in postmitotic neurons resulted in symptoms of severe motor dysfunction, while transgene expression in Mecp2 mice rescued the RTT phenotype. This is promising as a gene therapy for RTT, but care should be taken to avoid overexpression.
Studies on behavior in animal models
Animal models demonstrate that Mecp2 is not required for the proper development of neurons but rather is required to maintain their correct postmitotic function [7 ] . Mecp2 (308/Y) mice showed abnormal home-cage diurnal activity and abnormalities in social interaction. They showed deficits in nest building and decreased nest use [52 ] . Mutant female mice took less initiative and were less decisive approaching unfamiliar males, and spent less time in close vicinity to them in several social interactions. This study is important in showing that MECP2 mutations cause abnormalities in subcortical structure, and that these induce abnormalities in instinctive social behavior. This relates to the presence of autistic behaviors in RTT.
Treatment
Unfortunately, no successful treatments have been established. However, trials of theoretically attractive treatments have been reported. Ramaekers and Blau [53 ] reported a novel neurometabolic syndrome of cerebral folate deficiency (CFD) and its oral treatment with 5 formyltetrahydrofolate (folinic acid). They suggest the appropriateness of this therapy for RTT, one of the secondary forms of CFD.
Seizure is one of the common symptoms of RTT which appears in early childhood; however, there are no antiepileptics specifically recommended for RTT. Topiramate has GABAergic and glutaminergic effects, and both systems are affected in RTT.
Topiramate administered to eight patients with RTT, in two as monotherapy and six as adjunctive therapy, showed favorable effects in seven of the patients. Furthermore, respiratory abnormalities were improved (by 50-75%, and in two patients by 20-50%) [54 ] .
Lotan et al. [55 ] investigated the feasibility of a physical exercise program with treadmill for persons with RTT. With four females with RTT, aged 8.5-11 years, after a period of 2 months, they revealed considerable improvement in physical fitness and general functional ability, and all items of functional ability measurement as well as locomotion. As abnormality in locomotion is the initial and pathognomonic sign of RTT, these effects are considerable.
In RTT patients, visual and auditory perception is fairly well preserved, and failure in neural networks for cognition causes severe mental retardation. 
Screening large deletions
MECP2 mutations are not detected in about 20% of classic RTT patients. It was hypothesized by Laccone et al. [58 ] that larger deletions arising from a deletionprone region (DPR) occur commonly and are not being detected by current PCR-mediated screening methods. They found a large deletion in 10 out of 140 patients in whom RTT was strongly suggested and in 5 out of 31 classic RTT patients, recommend including quantitative analysis of the genomic sequences flanking the deletion-prone region in routine mutation screening. A single-tube quantitative PCR assay was developed for rapid determination of MECP2 gene dosage which is reliable for screening large rearrangements in RTT [59 ] .
Conclusion
Progress in studies on MECP2 and related genes has clarified the marked phenotypical variation of RTT, and studies on the role of MeCP2 during the maturation of the nervous system give insight into the age-related occurrence of the symptoms of RTT. However, most studies have been on disturbances of higher cortical function or dysfunction of the cortex. In RTT, the initial symptoms are hypotonia, failure in locomotion and abnormalities of sleep parameters, which develop in early infancy. This postulates dysfunction of the aminergic neurons of the brainstem which could cause abnormalities or failure in synaptogenesis in the brain and also could induce autism as well as autistic features of RTT. Molecular biological studies of these brainstem neurons and subcortical structures are necessary. Taking Rett syndrome as a prototypical neurodevelopmental disorder, the authors reviewed clinical to molecular biology reports on RTT and related disorders. They suggest regression as the common pathology and discuss the molecular involvement. Studies using Korean patients with RTT on MECP2 gene mutation revealing that XCI modifies the phenotype while it is primarily determined by the type and site of the mutation. The author, based on his own studies, classifies the basic mechanisms of plasticity during development and explains the characteristics of the brain plasticity of children, dividing them into four types. Against this background, the author discusses the fundamental mechanism for brain plasticity in pediatric neurological disorders including RTT. An excellent review considering the basic science of RTT. Report of a patient with Down syndrome who was clinically diagnosed as RTT at 18 months, and in whom an R168X mutation was detected at 12 years of age in addition to trisomy 21.
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